Technology | Drug-Eluting Balloons | July 26, 2017

FDA Clears Spectranetics Stellarex Drug-Coated Balloon

Stellarex produces top-tier clinical outcomes with a low drug dosage for patients with peripheral arterial disease

Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon

July 26, 2017 — The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the Stellarex drug-coated balloon (DCB). The device is designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).

This is the third drug-coated balloon to gain FDA clearance, joining the previously cleared Medtronic In-Pact Admiral and the C.R. Bard Lutonix. Read about the first FDA approvals in the article “Drug-eluting Balloons Enter the U.S. Market.”

The Stellarex DCB has shown safety and efficacy in a cohort of patients which included a higher preponderance of diabetics and core-lab defined severely calcified lesions in the U.S. investigational device exemption (IDE) trial. These results, in combination with the cohort of patients studied in the European Randomized Controlled Trial, demonstrate the Stellarex DCB is safe and effective in diverse patient populations when addressing symptomatic femoropopliteal disease,” stated Prakash Krishnan, M.D., ILLUMENATE Pivotal Trial’s co-principal investigator, Mount Sinai in New York.

Sean Lyden, M.D., ILLUMENATE Pivotal Trial’s co-principal investigator, Cleveland Clinic, Cleveland, Ohio added, “The ILLUMENATE Pivotal Trial treated a challenging patient population with a low paclitaxel drug dose. When considering options, I think most clinicians would prefer to use a lower drug dose if they can also achieve great patency results.”

Throughout the ILLUMENATE Trial Series, the Stellarex DCB’s EnduraCoat Technology demonstrates both safety and efficacy with consistently high patency rates and low clinically driven target lesion revascularization rates in a range of lesion complexities and patient co-morbidities. The device offers both hybrid paclitaxel crystallinity and a durable excipient to provide efficient drug transfer, effective drug residency with high coating durability and minimal particulate loss.

There are five ILLUMENATE clinical studies evaluating the safety and efficacy of the Stellarex DCB platform and supporting United States regulatory filings:

  • The ILLUMENATE EU Randomized Study is a prospective, randomized controlled, multi-center trial with 328 patients.  The primary safety and effectiveness endpoints at 12 months were met and superiority over percutaneous transluminal angioplasty (PTA) was demonstrated in both. The 12-month primary patency rate was 83.9 percent (188/224) in the Stellarex arm vs. 60.6 percent (40/66) in the PTA arm (P<0.001), per Kaplan Meier (KM) estimate the patency rate at day 365 was 89 percent vs. 65 percent, respectively (log-rank p<0.001);
  • The ILLUMENATE Pivotal Study is a prospective, randomized controlled, multi-center trial with 300 patients enrolled. The cohorts were well match and included a preponderance of patients with diabetes (50 percent) and severely calcified lesions (44 percent). The primary safety and effectiveness endpoints at 12 months were met and superiority over PTA was demonstrated in both. The primary patency rate was significantly higher in the Stellarex group at 76.3 percent (135/177) vs. 57.6 percent (53/92) for PTA (p=0.003). The 12-month primary patency rate, per KM estimate at day 365 was 82.3 percent in the DCB arm vs. 70.9 percent in the PTA arm (p=0.002);
  • The ILLUMENATE Global Study is a prospective, multi-center, single-arm study with 371 patients enrolled. The 12-month primary patency rate was 81.4 percent per KM estimate;
  • The ILLUMENATE First-In-Human (FIH) Study was a non-randomized, multi-center study that enrolled 80 patients. In the pre-dilatation arm (n=50), the primary patency rate per KM estimate was 89.5 percent at 12 months and 80.3 percent at 24 months; and
  • The ILLUMENATE Pharmacokinetic Study measured the paclitaxel drug levels in the blood of 25 patients and showed all patients had detectable paclitaxel levels after DCB deployment that declined rapidly within the first hour (54.4±116.9 ng/mL to 1.4±1.0 ng/mL).

Covidien originally developed the Stellarex and gained European CE mark approval in January 2015. In 2015, Covidien sold the Stellarex DCB platform to Spectranetics.  Spectranetics received Eurpean CE mark approval for a 0.014-inch version of the device in late 2016.

 

Watch the VIDEO “Drug-coated Balloons Enter the U.S. Market,” and interview with Doug Drachman, M.D., Mass General Hospital, who served a the site principal investigator for the Lutonix balloon trial.

 

For more information: www.spectranetics.com

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init